DIA

Korea Regulatory Science Center

DIA-KRSC Workshop 2024

Advancing Regulatory Science of Innovative Medicines for Global Convergence

26 September 2024
The-K Hotel Seoul, Korea

Overview

Since the COVID-19 pandemic, the development of medical products based on the latest innovative technologies has accelerated, and the global pharmaceutical market is expanding rapidly. This has made regulatory science more important than ever.

The Korea Regulatory Science Center (KRSC) and DIA jointly organized a workshop entitled "Advancing Regulatory Science of Innovative Medicines for Global Convergence". With 2024 KRSC-DIA Workshop on September 26th in Seoul, immediately following the 2024 DIA Asia Meeting, will provide you with a unique opportunity to discuss the regulatory perspectives and innovations first hand.

The topics in each session:

Session I : Regulatory science perspective on Drug development using innovative tools- Current status and future directions of regulatory science for innovative medicines. Regulatory convergence and exchange of information on the regulatory framework and any proposed changes from US, Europe, and Asian countries.

Session II : Advancing Pharmacovigilance - Regulatory Use of Database and Risk Management Plan.

Session III : Regulatory Science Strategies and Case Study for Innovative Drug Development. In-depth quality control and safety assessment strategies for innovative new drugs.

Objective:

- Gain a comprehensive understanding of the latest innovations and changes in the biohealth sector, including medical product development
- Get updates on global regulatory policies, review processes, and safety assessments for innovative new drugs
- Get insight into the safety measures in place to protect people during the development and use of innovative medicines
- Discuss the future of the regulatory science of medicines using cutting-edge technologies
- Accelerating the development of innovative medicines through regulatory science collaborations

Program Chair

Yil-Seob Lee, MD, PhD
CHA Bundang Medical Center

Program Committee

In-sook Park, PhD
Korea Regulatory Science Center

Joonwoo Bahn, MD, PhD
Asan Medical Center

Deborah Chee, MD, PhD, MBA
Gateway Sciences

Youngju Choi, PhD
NIFDS, MFDS

Hyung-Jin Jung, MD
Janssen Korea

Younglim Kim, PhD
NIFDS, MFDS

Sora Lee
Syneos Health

Si-Nae Lee, M.Pharm
Modona Korea

Eui-Kyung Lee, PhD
Sungkunkwan University

Min-Jung Lim, MS
MediSafe

So Ra Park, MD PhD
Regenerative Medicine Acceleration Foundation

Misun Park, PhD
Korea Regulatory Science Center

Hyou Young Rhim, MD
Yuhan Pharm inc.

Juyoung Shin, PhD
Sungkunkwan University

SeungYoung Song
Janssen Korea

Hyejong Yoo, M.Pharm
AstraZeneca Korea

Young Joo Park, PhD
Korea, Singapore, and Southeast Asia, DIA

DIA

The Drug Information Association, Inc.
DIA Global Center: Washington, DC, USA | Basel, Switzerland | Beijing, China | Horsham, PA, USA | Mumbai, India | Tokyo, Japan

DIA volunteers, members, and staff provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications, and educational materials, throughout the year, all around the world.

DIAglobal.org

AGENDA | September 26, 2024 | ALL TIMINGS IN KST

8.30 – 9.00 am	Registration
9.00 – 9.10 am	**Opening Remarks**
	In-sook Park, Director General, KRSC
9.10 – 9.20 am	**Congratulation Remark**
	Young Joo Park, Vice President, Korea, Singapore, and Southeast Asia, DIA **Yunhong Noh**, President, KPBMA
9.20 am – 12.20 pm	**Session 1.** **Regulatory science perspective on Drug development using innovative tools**
	This session aims to explore the regulatory perspective for drug development using innovative tools including Artificial Intelligence (AI), Machine Learning (ML) and digital health technologies. We will explore how the regulatory science has advanced to foster innovation while protecting public health. The session will cover the regulatory framework progress in this area and panel session will provide the various insights on regulatory challenges and future direction.
Session Chairs	**Kyungwon Seo** Professor Dongguk University **Younglim Kim** Director General, Drug Evaluation Department, MFDS
9.20 – 9.40 am	Opportunities and challenges in Clinical Trial Innovation
	Meghana Chalasani, FDA/CDER/OND Associate Director for Clinical Trial Innovation, US
9.40 – 10.00 am	The European Medicines Agency's scientific guidelines on artificial intelligence to help medicine developers for prepareing marketing authorisation applications
	EMA Speaker, TBD
10.00 – 10.20 am	Japan's approach to AI regulation on clinical trials
	Japan Speaker, TBD
10.20 – 10.40 am	Updates of medical product regulation in relation to innovative technology in Korea
	Sohee Kim, Director, Cardiovascular & Neurology Products Division, MFDS
10.20 – 10.40 am	Current state of innovative tools utilization in drug development, clinical trial and registration in Korea
	Junhee Pyo, Vice Chief, Convergence AI Institute for Drug Discovery, KPBMA
11.00 – 11.30 am	**Coffee Break & Networking**
11.30 – 12.20 pm	**Panel Discussion + Q&A**
	Chair : **Kyungwon Seo,** Dongguk University Panellists: **Meghana Chalasani,** FDA, US **EMA Speaker, TBD** **Japan Speaker, TBD** **Hae Sun Suh,** Kyunghee Univesity **Minseok Kim,** JNPMEDI **Sohee Kim**, MFDS **Junhee Pyo**, KPBMA
12.20 – 1.40 pm	**Lunch & Networking**

AGENDA | September 26, 2024 | ALL TIMINGS IN KST

1.40 – 3.45 pm	**Session 2.** **Advancing Pharmacovigilance: regulatory use of database and Risk Management Plan**
	This session aims to explore the evolving role of databases and Risk Management Plans (RMPs) in pharmacovigilance to ensure the safety and efficacy of medicinal products post-approval. Attendees will gain insights into the utilization of real-world data and advanced data analytics for regulatory decision-making, enhancing post-marketing surveillance, and improving risk management strategies. Through case studies and regulatory perspectives from different regions, the session will highlight best practices, challenges, and future directions for integrating database studies and RMPs into pharmacovigilance frameworks.
Session Chairs	**Min-Jung Lim** CEO MediSafe **In-sook Park** Director General KRSC
1.40 – 2.05 pm	Use cases of database study for the post-marketing surveillance in PMDA
	Takashi WAKI, Division of Pharmacoepidemiology, PMDA
2.05 – 2.30 pm	Case studies on safety information analysis and regulatory reflection using CDM
	Bonggi Kim, Director, Office of Pharmacoepidemiology and Big Data Analytics, KIDS
2.30 - 2.55 pm	Recent use cases of real-world data for regulatory decision-making in EU
	Belgian Regulator, TBD
2.55 – 3.45 pm	**Panel Discussion + Q&A**
	Juyoung Shin, Professor, Sungkunkwan Univesity **Takashi WAKI,** Division of Pharmacoepidemiology, PMDA **Bonggi Kim,** Director, Office of Pharmacoepidemiology and Big Data Analytics, KIDS **EMA Speaker,** TBD **Hyung-Jin Jung**, Sr.Director, Janssen Korea **Younglim Kim**, Deputy Director, Biopharmaceutical Quality Management Division, MFDS **Nam-Kyong Choi**, Professor, Ewha women's University
3.45 – 4.10 pm	**Session 3.** **Regulatory Science Strategies and Case Study for Innovative Drug Development**
	This session aims to explore the regulatory science strategies and case studies essential for the innovative drug development sector. We will examine the quality review trends of advanced drugs, focusing on recent developments in CMC reviews and guidelines. The session will cover the clinical and regulatory development of platform-based drugs including synthetic peptide drugs. Additionally, case studies on clinical development and approval of innovative drugs, including cell and gene therapies will be presented.
Session Chairs	**Youngju Choi** Director General, Biopharmaceutical and Herbal Medicine Evaluation Department, MFDS **Sora Lee** Vice President, General Manager Korea, Syneos Health
3.45 – 4.10 pm	The direction of quality review for advanced drugs in Korea : Recent CMC Review Trend of Advanced Drug in Korea
	Ohseok Kwon, Deputy Director, Advanced Drug Quality Division, MFDS
4.10 – 4.35 pm	Regulatory perspectives for advanced drug in US FDA / EMA
	FDA/EMA Speaker, TBD
4.35 – 5.00 pm	Case Study on the Application of Regulations in Clinical Development and New Drug Approval for Cell and Gene Therapies
	Abhi Gupta, Senior Vice President, Head of Cell & Gene Therapy, Syneos Health
5.00 – 5.25 pm	Global CMC Regulatory Perspectives for Cell and Gene Therapy Development and Commercialization
	Allen Callaway, Director CMC Regulatory Affairs, Janssen
5.25 – 5.30 pm	**Closing**

REGISTRATION FORM : Register online or forward to DIA
Tel +82-10-9014-9582

DIA KRSC Workshop 2024

Event #24380 • 26 September, 2024 | The-K Hotel Seoul, Korea

REGISTRATION

Register online at the link below or complete this registration form and email to our Korea Office

Online Registration For Payment via Credit Card, please access here

DIA will send participants a confirmation letter within 10 business days after receipt of their registration.

Registration Fees If DIA cannot verify your membership, you will be charged the nonmember fee. Registration fee includes refreshment breaks and reception (if applicable), and will be accepted by mail, fax, or online.

25% Discount is applicable for those who attend both events!

*Please note that the discount is only available when registering for both events at the same time. **Before WEB registration, please contact** Korea@diaglobal.org**"**

Exploring ASIA MEETING 2024 Click Here			REGISTRATION FEE (KRW)	
	Early Bird (until 13 Sep, 2024)		25. SEP ASIA MEETING	26. SEP DIA - KRSC WORKSHOP
MEMBER	**Academic**	**Early Bird**	❑200,000	❑130,000
		After 14 Sep, 2024	❑250,000	❑180,000
	Government	**Early Bird**	❑200,000	❑130,000
		After 14 Sep, 2024	❑250,000	❑180,000
	Industry	**Early Bird**	❑300,000	❑200,000
		After 14 Sep, 2024	❑350,000	❑250,000
NON-MEMBER	**Academia**	**Early Bird**	❑250,000	❑180,000
		After 14 Sep, 2024	❑350,000	❑230,000
	Government	**Early Bird**	❑250,000	❑180,000
		After 14 Sep, 2024	❑350,000	❑230,000
	Industry	**Early Bird**	❑350,000	❑250,000
		After 14 Sep, 2024	❑450,000	❑300,000
Patient / Patient Advocacy Groups			❑100,000	❑100,000
Students			❑100,000	❑100,000
Sponsorship & Group Registration Contact : korea@diaglobal.org				

Please check the applicable category:

❑ Academia ❑ Government ❑ Industry

Last Name

First Name

Degrees ❑ Dr. ❑ Mr. ❑ Ms.

Job Title

Company

Address (As required for postal delivery to your location)

City State Zip/Postal Country

email **Required for confirmation**

Phone Number **Required**

Join DIA now to save on future meetings and to enjoy the benefits of membership for a full year: www.DIAglobal.org/Membership

❑ I **DO** want to be a DIA member

❑ I **DO NOT** want to be a DIA member

CONTACT INFORMATION

tel: +82-10-9014-9582
email: Korea@DIAglobal.org
www.diajapan.org

DIA Terms and Conditions

CANCELLATION POLICY: On or before 12 Aug, 2024 Administrative fee that will be withheld from refund amount: the administrative fee that will be withheld from refund amount is 25 % of the delegate fee

Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid.

Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but **membership is not transferable**. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.

EVENT STREAM AND RECORDING

If you attend a DIA event, we make video and audio recordings of events (both face to face and online) that may include your participation in the event, including your image, questions and comments. To view our full photography and video recording policy, click **here**. (https://www.diaglobal.org/general/photography-policy)

PRIVACY STATEMENT

The personal information you request will be used for the purpose of sending conference information from DIA. In addition, in the web conference, we will use the information with the name of the company or organization and the name of everyone who participates, and it will be used for networking with participants, related parties, exhibiting companies for the period and about two weeks after the event. .. By submitting this application form, it is interpreted that you have consented to the above handling of personal information, but if you do not agree, please contact DIA.

By signing below I confirm that I agree with DIA's Terms and Conditions of booking. These are available from the office or online by clicking **here**. (https://www.diaglobal.org/general/photography-policy)

Signature Date

PAYMENT DETAILS

Wire Transfer Instructions for DIA Japan:
MIZUHO BANK LTD (0001)
KAMIYACHO Branch (146)
Ordinary AC #1273382
SH DIA Japan
5-1-5 Toranomon, Minato-ku 105-0001 Tokyo Japan
SWIFT CODE:MHCBJPJT

PAYMENT OPTIONS

Register online at **www.DIAglobal.org** or check payment method.

❑ **BANK TRANSFER:**

You will recieve an invoice with bank information detail by email after registration completion.

All local and overseas charges incurred for the bank transfer must be borne by payer.

❑ **CREDIT CARD (VISA OR MASTERCARD OR AMEX ONLY)**

❑ **VISA** ❑ **MC** ❑ **AMEX** Exp. (mm/yy) _____

Card No.

Cardholder Name

Signature

DIA